Market Cap 14.08M
Revenue (ttm) 0.00
Net Income (ttm) -10.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 53,516
Avg Vol 348,204
Day's Range N/A - N/A
Shares Out 13.67M
Stochastic %K 98%
Beta 1.62
Analysts Sell
Price Target $10.17

Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 9 799 6183
Address:
Building B, 11 HaMenofim Street, Herzliya, Israel
knowthyself
knowthyself Jan. 14 at 7:21 PM
$NRSN man, when will we get some news?
0 · Reply
Itay_Bio_Invest
Itay_Bio_Invest Jan. 14 at 6:39 PM
$NRSN Q1 2026
0 · Reply
rml360
rml360 Jan. 14 at 4:03 PM
$NRSN I am not sure how we are still holding a dollar
0 · Reply
Speculator2
Speculator2 Jan. 14 at 2:43 AM
$NRSN Today, the borrow fee climbed to 17.72% with 200k shares available. NRSN is experiencing a long-driven momentum move with passive short resistance, not a short-driven unwind but this could change rapidly.
0 · Reply
supernoob
supernoob Jan. 13 at 3:19 PM
$NRSN we need $5 to start trending
2 · Reply
knowthyself
knowthyself Jan. 13 at 1:14 PM
$NRSN someone mentioned something about the Corporate Deck has removed "partnership" catalyst. When was the presentation revised?
1 · Reply
mmtiddy
mmtiddy Jan. 13 at 6:28 AM
$NRSN They need this partner, ATM, offerings, private placements cant fund this trial, Alon’s bonus will be in shambles too, dude has $800,000 worth of shares given to himself since he can’t pay a salary to himself for the last 4 years. I hope they are entertaining multiple partners and sign this off at the best value for everyone involved
0 · Reply
mmtiddy
mmtiddy Jan. 13 at 6:23 AM
$NRSN A strange observation but their new slide deck has no mention of the NOC resubmission or partnership, it was removed from their slide ”Upcoming Catalysts” A strange omission no? Wouldnt you want to keep it if cash position currently is so low and doesnt make sense how they continue both the AD and ALS trials
0 · Reply
mmtiddy
mmtiddy Jan. 12 at 10:21 AM
$NRSN Something brewing ? Stock is up 50% in the last 2 weeks, has the bald man finally done it?
1 · Reply
Stekli27
Stekli27 Jan. 11 at 7:49 PM
$NRSN One more thing people overlook: NRSN is one of maybe a handful out of hundreds of microcaps that actually offers meaningful near-term upside with a real pipeline, not just a single binary hope. Targeted patient selection via NeuroKaire + a de-risked lead asset in ALS + a genuine Alzheimer’s wildcard is rare asymmetric setup at this market cap. On top of that, a validated CDMO (Recipharm) is already in place and essentially waiting for the green light, which removes a major execution risk many microcaps never solve. High risk, yes. But the risk/reward is clearly skewed. Good luck to all of you. ☘️
1 · Reply
Latest News on NRSN
NeuroSense to Host Investor Webinar on December 8, 2025

Nov 3, 2025, 9:15 AM EST - 2 months ago

NeuroSense to Host Investor Webinar on December 8, 2025


NeuroSense Announces First Quarter 2024 Business Update

May 2, 2024, 9:19 AM EDT - 1 year ago

NeuroSense Announces First Quarter 2024 Business Update


knowthyself
knowthyself Jan. 14 at 7:21 PM
$NRSN man, when will we get some news?
0 · Reply
Itay_Bio_Invest
Itay_Bio_Invest Jan. 14 at 6:39 PM
$NRSN Q1 2026
0 · Reply
rml360
rml360 Jan. 14 at 4:03 PM
$NRSN I am not sure how we are still holding a dollar
0 · Reply
Speculator2
Speculator2 Jan. 14 at 2:43 AM
$NRSN Today, the borrow fee climbed to 17.72% with 200k shares available. NRSN is experiencing a long-driven momentum move with passive short resistance, not a short-driven unwind but this could change rapidly.
0 · Reply
supernoob
supernoob Jan. 13 at 3:19 PM
$NRSN we need $5 to start trending
2 · Reply
knowthyself
knowthyself Jan. 13 at 1:14 PM
$NRSN someone mentioned something about the Corporate Deck has removed "partnership" catalyst. When was the presentation revised?
1 · Reply
mmtiddy
mmtiddy Jan. 13 at 6:28 AM
$NRSN They need this partner, ATM, offerings, private placements cant fund this trial, Alon’s bonus will be in shambles too, dude has $800,000 worth of shares given to himself since he can’t pay a salary to himself for the last 4 years. I hope they are entertaining multiple partners and sign this off at the best value for everyone involved
0 · Reply
mmtiddy
mmtiddy Jan. 13 at 6:23 AM
$NRSN A strange observation but their new slide deck has no mention of the NOC resubmission or partnership, it was removed from their slide ”Upcoming Catalysts” A strange omission no? Wouldnt you want to keep it if cash position currently is so low and doesnt make sense how they continue both the AD and ALS trials
0 · Reply
mmtiddy
mmtiddy Jan. 12 at 10:21 AM
$NRSN Something brewing ? Stock is up 50% in the last 2 weeks, has the bald man finally done it?
1 · Reply
Stekli27
Stekli27 Jan. 11 at 7:49 PM
$NRSN One more thing people overlook: NRSN is one of maybe a handful out of hundreds of microcaps that actually offers meaningful near-term upside with a real pipeline, not just a single binary hope. Targeted patient selection via NeuroKaire + a de-risked lead asset in ALS + a genuine Alzheimer’s wildcard is rare asymmetric setup at this market cap. On top of that, a validated CDMO (Recipharm) is already in place and essentially waiting for the green light, which removes a major execution risk many microcaps never solve. High risk, yes. But the risk/reward is clearly skewed. Good luck to all of you. ☘️
1 · Reply
forza_juve
forza_juve Jan. 10 at 2:00 PM
$NRSN With the price closing above $1, it has restarted the 30-business day (under the $1 compliance rule). That’s the silver lining. Adding that expert two days ago, that’s the bronze lining. Now for the gold lining, show us a partner for phase 3 with minimal dilution. Also keep an eye out for results in Q1 (2026) on the additional testing. Something positive there could make the price jump significantly (at least enough for some people to get out with a profit if they don’t want to wait for a partner sometime in 2026 or Canada approval by end of 2026)
0 · Reply
Speculator2
Speculator2 Jan. 10 at 4:13 AM
$NRSN I am curious to know what the CEO replied to this shareholder https://www.linkedin.com/posts/alonbn_als-activity-7415497595445440512-Oh8c but how fitting to post this on a day the share price crosses $1 again after a disastrous month
1 · Reply
supernoob
supernoob Jan. 9 at 8:17 PM
$NRSN I’ll be even at $1.2 🥲
0 · Reply
Babilon1210
Babilon1210 Jan. 9 at 6:39 PM
$NRSN Nice!
0 · Reply
posyche
posyche Jan. 9 at 6:37 PM
$NRSN only down 1.06 since right before the "big announcement"!....or should I say BIG ANNOUNCEMENT...lol
0 · Reply
Oldpuck
Oldpuck Jan. 9 at 5:13 PM
$NRSN Any hope for this stock still a bag holder a little smaller bag though.
1 · Reply
Speculator2
Speculator2 Jan. 9 at 5:11 PM
$NRSN Schwab only allows closing positions via its online portal. Once it removes this restriction, the stock might climb even more. December effect was brutal, selling losing positions to reduce capital gains, but the January effect seems to apply here. It has been up 30% in just a week. Of course, the elephant in the room is around financing, and the partnership they have been talking about for over a year. We might never know why it did not materialize last Spring or Summer, but the company is still there and now expected to release data on Alzheimer later this quarter. How would positive data impact a potential partnership or other financing venue? Yesterday's news is positive but not enough to support a continuous rise of the SP. Now, if we can avoid being non-compliant with Nasdaq $1 rule that would be great.
0 · Reply
supernoob
supernoob Jan. 9 at 4:20 PM
0 · Reply
Drugtrade
Drugtrade Jan. 9 at 3:43 PM
$NRSN wish i got in at .70 as usual it held there.. resilient stock but still skeptical of cash on hand
0 · Reply
iBoughtTheWrongTicker
iBoughtTheWrongTicker Jan. 9 at 3:38 PM
$NRSN alrrrright you dragged me back in
0 · Reply
knowthyself
knowthyself Jan. 9 at 12:49 PM
$NRSN still trying to figure out what biomarkers/tests measured efficacy in the Ph2 ALZ trial? Anyone care to bite? I'm genuinely curious. As I said, yesterday I jumped back in, getting a decent entry at .86. Though the Ph2 trial was all about safety, we already know from the ALS trial that PrimeC is safe. They obviously had a keen eye on efficacy. So I ask two quesrions: 1) why didn't they mention anything about efficacy in the Dec pr? And 2) what did the M.D. from Harvard see to make him join the Scientific Advisory Board? (I don't know shit, but I do know even to know a man like him has better things to do with his prestige than collaborate with an insolvent, one-drug microcap that doesn't have enough money to start a Ph3 trial.)
1 · Reply
IrishSean
IrishSean Jan. 9 at 12:46 PM
$NRSN Reflecting on Arnold joining the SAB, I think it de-risks the AD pivot, which is a massive market (15B+ vs. ALS’s 1-2B) and could open doors for Big Pharma interest (e.g. Biogen or Roche, given their neuro focus). That said if AD data flops, this hire might get overlooked, but overall it reinforces NRSN as a serious player in neurodegeneration rather than a one trick ALS pony. I’m not a fan of the CEO or their IR but snagging a heavyweight like him signals internal optimism about upcoming data and boosts external credibility with investors, regulators and potential partners. Still a high risk high reward investment but the hire is bullish.
1 · Reply